WuXi Biologics (Cayman) (HKSE:02269) Net Income (Continuing Operations) : HK$4,228 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. WuXi Biologics (Cayman)'s Net Income (Continuing Operations) for the six months ended in Dec. 2024 was HK$2,312 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$4,228 Mil.

WuXi Biologics (Cayman) Net Income (Continuing Operations) Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Net Income (Continuing Operations) Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

2,006.58

4,296.14

5,080.95

3,905.47

4,212.36

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															2,153.79	2,557.11	1,348.37	1,916.58	2,311.58

WuXi Biologics (Cayman) Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$4,228 Mil.

WuXi Biologics (Cayman) (HKSE:02269) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

WuXi Biologics (Cayman) Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (HKSE:02269) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.

Executives

Blackrock, Inc.	2201 Interest of corporation controlled by you
Li Ge	2201 Interest of corporation controlled by you
Liu Xiaozhong	2401 A concert party to an agreement to buy shares
New Wuxi Life Science Holdings Limited	2201 Interest of corporation controlled by you
New Wuxi Life Science Limited	2201 Interest of corporation controlled by you
Wuxi Biologics Holdings Limited	2101 Beneficial owner
Wuxi Pharmatech (cayman) Inc.	2201 Interest of corporation controlled by you
Zhang Zhaohui	2401 A concert party to an agreement to buy shares
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Brown Brothers Harriman & Co.	2502 Approved lending agent
Zhao Ning	2202 Interest of your spouse
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you

WuXi Biologics (Cayman) Headlines

No Headlines